Show simple item record

dc.contributor.authorSaluja, Hariti
dc.contributor.authorKarapetis, Christos Stelios
dc.contributor.authorPedersen, Susanne K
dc.contributor.authorYoung, Graeme Paul
dc.contributor.authorSymonds, Erin
dc.date.accessioned2018-09-14T03:02:24Z
dc.date.available2018-09-14T03:02:24Z
dc.date.issued2018-07-24
dc.identifier.citationSaluja, H., Karapetis, C.S., Pedersen, S.K., Young, G.P. and Symonds, E.L., (2018). The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. Front. Oncol. 8:275. doi: 10.3389/fonc.2018.00275.en_US
dc.identifier.issn2234-943X
dc.identifier.urihttp://hdl.handle.net/2328/38288
dc.descriptionNote: This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.description.abstractGastrointestinal cancers, including oesophageal, gastric and colorectal cancers (CRC) have high rates of disease recurrence despite curative resection. There are a number of recent studies that have investigated the use of circulating tumor DNA (ctDNA) for prognostic value in these cancers. We reviewed studies that had been published prior to March 2018 that assessed the prognostic values of ctDNA in patients with oesophageal and gastric cancers, gastrointestinal stromal tumors (GIST) and CRC. We identified 63 eligible clinical studies that focussed on recurrence and survival. Studies assessed investigated various ctDNA biomarkers in patients with different stages of cancer undergoing surgical resection, chemotherapy and no treatment. For oesophageal squamous cell carcinoma and oesophageal adenocarcinoma, methylation of certain genes such as APC and DAPK have been highlighted as promising biomarkers for prognostication, but these studies are limited and more comprehensive research is needed. Studies focusing on gastric cancer patients showed that methylation of ctDNA in SOX17 and APC were independently associated with poor survival. Two studies demonstrated an association between ctDNA and recurrence and survival in GIST patients, but more studies are needed for this type of gastrointestinal cancer. A large proportion of the literature was on CRC which identified both somatic mutations and DNA methylation biomarkers to determine prognosis. ctDNA biomarkers that identified somatic mutations were more effective if they were personalized based on mutations found in the primary tumor tissue, but ctDNA methylation studies identified various biomarkers that predicted increased risk of recurrence, poor disease free survival and overall survival. While the use of non-invasive ctDNA biomarkers for prognosis is promising, larger studies are needed to validate the clinical utility for optimizing treatment and surveillance strategies to reduce mortality from gastrointestinal cancers.en_US
dc.description.sponsorshipCK and GY are recipients of grant funding from Cancer Council SA’s Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health, and Flinders Foundation through the generous support of its donors.en_US
dc.language.isoenen_US
dc.publisherFrontiers Mediaen_US
dc.rightsCopyright © 2018 Saluja, Karapetis, Pedersen, Young and Symonds. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.subjectcirculating tumor DNAen_US
dc.subjectcolorectal canceren_US
dc.subjectoesophageal canceren_US
dc.subjectgastric canceren_US
dc.subjectgastrointestinal stromal tumoren_US
dc.subjectcell free circulating DNAen_US
dc.subjectsurvivalen_US
dc.subjectrecurrenceen_US
dc.titleThe use of circulating tumor DNA for prognosis of gastrointestinal cancersen_US
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.3389/fonc.2018.00275en_US
dc.rights.holderCopyright © 2018 Saluja, Karapetis, Pedersen, Young and Symonds.en_US
dc.rights.licenseCC-BY
local.contributor.authorOrcidLookupSymonds, Erin: https://orcid.org/0000-0003-2451-0358en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record